Buyers widening their own doors: demand already secured, far-side receiving constraint now being cleared
The model's full reasoning — Q4 2023 call → NOWe need to determine if the transcript conveys a situation where: (1) demand/business is real and already in hand, (2) the binding constraint is on the receiving side (counterparties' capacity to take/absorb), and (3) those counterparties are already working on clearing that constraint, with the business mostly ahead of reported results. Let's analyze the transcript. The main programs: dermal filler with AbbVie, breast implants, gut-on-a-chip (put on hold), and bioinks with Stratasys. For the AbbVie collaboration: They achieved a milestone, got $10M. The product is in clinical phase. They mention AbbVie expects growth in aesthetics market. But there's no description of a receiving-side constraint like AbbVie's capacity to absorb. The constraint is not described as AbbVie's readiness. The business is development, not delivery of product. The milestone payments are tied to development milestones, not receiving-side capacity. So not that. For breast implants: They are doing large animal studies. No mention of counterparties' receiving capacity. The constraint is their own development. For gut-on-a-chip: put on hold. For Stratasys collaboration: They are developing a printing solution. No mention of receiving-side constraint. The question asks: does management convey that the company already has business or demand that is secured or arriving, but the thing standing between them and larger delivered business is the counterparties' own ability to receive/install/qualify etc., and that those counterparties are already working on that preparation? The transcript does not describe such a situation. The only mention of demand is AbbVie's expectation of market growth, but that's not a receiving-side constraint. The company's own programs are in development. There is no description of a bottleneck on the receiving side. The company is not delivering product to customers; it's developing products. The only revenue is from sales of rhCollagen products and milestone payments. No mention of counterparties' capacity to absorb. Thus, answer NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| NC | NACCO Industries, Inc. | Q1 2024 | 2024-05-05 | C+ |
| LTRX | Lantronix, Inc. | Q3 2024 | 2024-04-29 | C |
| CTO | CTO Realty Growth, Inc. | Q2 2023 | 2023-07-28 | B |
| BXP | Boston Properties, Inc. | Q1 2022 | 2022-05-03 | A |
| EXP | Eagle Materials Inc. | Q3 2022 | 2022-01-27 | B |
| MKC | McCormick & Company, Incorporated | Q2 2018 | 2018-06-28 | C+ |
| BIIB | Biogen Inc. | Q2 2017 | 2017-07-25 | B |
| PDCO | Patterson Companies, Inc. | Q3 2017 | 2017-02-23 | C |
| ARAY | Accuray Incorporated | Q4 2016 | 2016-08-17 | B |
MKC · Q2 2018 → YESThe question is about whether management conveys that they already have secured business or demand, but the bottleneck is the counterparties' ability to receive, install, etc., and those counterpartie...**NO** The transcript describes a situation where McCormick has already won shelf-space changes and distribution improvements from retailers (customers have accepted the recommendations), but implementation is delayed due to retailers' own operational reset windows and competitor product sell-through. This is framed as a temporary, ongoing industry practice rather than a binding constraint being actively cleared right now to unlock a meaningfully larger volume of already-secured business. Management presents it as part of their category-management progress with runway ahead, not as counterparties clearing a receiving-side bottleneck that is already underway and will drive the bulk of the upside.
BIIB · Q2 2017 → YESThe question is about whether management conveys that they already have secured demand, but the bottleneck is the counterparties' ability to receive/install/etc., and those counterparties are already ...YES The transcript shows management conveying exactly this situation for SPINRAZA. Demand is already secured and arriving: “significant uptake in the U.S.” with “strong demand across patient types” and “roughly two third of patients treated to date having Type 2 or Type 3 SMA.” The binding constraint is on 60% of Type 2 patients who have had spinal surgery, creating intrathecal administration challenges on the receiving side.
BXP · Q1 2022 → YESThe question is about whether management conveys that they already have secured business or demand, but the bottleneck is the counterparties' ability to receive/install/etc., and those counterparties ...YES The transcript shows management conveying secured demand through signed leases totaling over 975,000 square feet on vacant space that have not yet commenced occupancy, plus an additional 1.3 million square feet in active negotiations and over 750,000 square feet in the development pipeline.